About China Health Holding
China Health Holding, Inc. is a developer, manufacturer and marketer for natural medicinal products and pharmaceutical drug pipeline in China and worldwide, with an extensive knowledge and expertise in the field of Traditional Chinese Medicine and China Pharmaceutical Industry. The Company's immediate goal is profitable penetration of the growing global and China pharmaceutical industry and market. Also to seek and develop and complete potential acquisition candidates with major pharmaceutical companies in PR China and worldwide to secure a strong future and powerful position in the global and PR China pharmaceutical industry. Long-term plans include the development of a pharmaceutical drug pipeline and technology based on the Company's access to the knowledge of Traditional Chinese Medicine and PR China pharmaceutical industry.
The Company is supported by two cores, wholly owned subsidiaries: 1. China Health World Pharmaceutical Corporation, which will develop, manufacture and commercialize natural medications for epidemic diseases and conditions related to mellitus, cardiovascular and cerebral-vascular system dysfunctions, and neurological disorders. 2. China Health World Trade Corporation, which will support the Company in the areas of worldwide to develop China Health’s retain/franchise stores/infrastructure and worldwide branding, multimedia marketing and multi-channel distribution to global customers and markets.
Recent Development and Acquisition Progress:
The Company controls/owns exclusive worldwide ownership/rights for a total of 134 proprietary natural herbal medicinal products/formulas as Two Natural Herbal Medicinal Product lines: King of Herbs products and Taoist Medicinal products. The Company is developing and execution for further worldwide branding, multimedia marketing and multi-channel distribution, and worldwide retail and franchise stores/infrastructure to global customers and markets.
CHHH has executed a definitive acquisition agreement to acquire 60% of Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd, and CHHH has executed a definitive acquisition agreement to acquire 100% of Shaanxi MeiChen Pharmaceuticals Co. Ltd.
CHHH recently has also entered into acquisitions letters of intent to acquire 51% or more of the following pharmaceutical companies in PR China with legal first refusal and exclusive rights with: Beijing Boran Pharmaceutical Co. Ltd.; and Shaanxi Wanan Pharmaceuticals Co. Ltd.; and Henan Tiankang Pharmaceuticals Co. Ltd.
CHHH believes that the completion of these acquisitions will enable it to vertically integrate its operations from manufacturing, developing and marketing Chinese herbal-based medicinal products, as well as a pharmaceutical drug pipeline, to full distribution and marketing across PR China, therefore substantially increasing profit margins. Acquisitions should accelerate growth of revenues and earnings. A strategic combination of assets, net income, an enhanced pharmaceutical drug pipeline and technologies will accrete value to the Company and its shareholders.
In addition, CHHH also recently signed a letter of intent with WangJing Hospital and the WangJing Hospital of China Academy of Chinese Medical Sciences, PR China, in order to develop the China International University of Traditional Chinese Medicine and the University Hospital for Traditional Chinese Medical Sciences.
About Investor Relations International
